| Cash Flow | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Net loss | -2,224,628 | -12,518,480 |
| Depreciation and amortization | 5,924 | 7,151 |
| Equity-based compensation | 213,044 | 219,058 |
| Change in fair value of warrant liability | NaN | -6,540 |
| In-process research and development expense | NaN | 8,517,966 |
| Prepaid expenses and other current assets | 261,821 | -419,628 |
| Accounts payable | -4,556 | -1,167,068 |
| Accrued expenses and other | -617,292 | -298,903 |
| Net cash used in operating activities | -2,889,329 | -4,827,188 |
| Issuance of promissory loan in connection with asset acquisition | NaN | 577,000 |
| Cash received from asset acquisition, net of cash paid | NaN | 1,341,735 |
| Net cash provided by investing activities | NaN | 764,735 |
| Proceeds from issuance of equity securities, net | 0 | 12,559,728 |
| Payments on note payable | 0 | 221,866 |
| Net cash provided by financing activities | 0 | 12,337,862 |
| Net decrease in cash | -2,889,329 | 8,275,409 |
| Cash, cash equivalents, and restricted cash at beginning of period | 10,709,937 | 2,434,528 |
| Cash, cash equivalents, and restricted cash at end of period | 7,820,608 | 10,709,937 |
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)